Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 65/100

Failure Rate

25.0%

1 terminated/withdrawn out of 4 trials

Success Rate

66.7%

-19.8% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

50%

1 of 2 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

No phase data available

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT01369030Completed

Deplin® P.L.U.S. Program (Progress Through Learning Understanding & Support)

Role: collaborator

NCT01370954Completed

NAC-003 P.L.U.S. Program (Progress Through Learning Understanding & Support)

Role: collaborator

NCT01358552Terminated

Néevo®/NéevoDHA® P.L.U.S. Program (Progress Through Learning, Understand & Support)

Role: collaborator

NCT01368549Unknown

Metanx® P.L.U.S. Program (Progress Through Learning, Understanding & Support)

Role: collaborator

All 4 trials loaded